Mecasermin
| Clinical data | |
|---|---|
| Trade names | Increlex |
| Other names | FK-780; Recombinant human insulin-like growth factor-1; rhIGF-1; Somatomedin-1 |
| AHFS/Drugs.com | Monograph |
| Pregnancy category |
|
| Routes of administration | Subcutaneous injection |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Elimination half-life | 5.8 hours[3] |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C331H512N94O101S7 |
| Molar mass | 7648.71 g·mol−1 |
  (what is this?) (verify) | |
Mecasermin, sold under the brand name Increlex, also known as recombinant human insulin-like growth factor-1 (rhIGF-1), is a recombinant form of human insulin-like growth factor 1 (IGF-I) which is used in the long-term treatment of growth failure and short stature in children with severe primary IGF-I deficiency, for instance due to growth hormone deficiency or Laron syndrome (growth hormone insensitivity).[3][4][5]
Mecasermin has a biological half-life of about 5.8 hours in children with severe primary IGF-1 deficiency.[3]
A related medication is mecasermin rinfabate (brand name Iplex), which is a combination of mecasermin (rhIGF-1), insulin-like growth factor binding protein-3 (IGFBP-3), and insulin-like growth factor binding protein acid labile subunit (IGFALS) as a ternary complex.[6] The complex serves to prolong the action of mecasermin in the human body; the half-life of mecasermin when provided as this complex is 13.4 hours in individuals with severe primary IGF-1 deficiency.[6]
Mecasermin therapy has been also shown to be beneficial in other conditions not related to growth failure, including diabetes mellitus and anorexia nervosa.[7]
References
- ^ a b https://www.tga.gov.au/resources/auspmd/increlex [bare URL]
- ^ "Summary Basis of Decision (SBD) for Increlex". Health Canada. 23 October 2014. Retrieved 29 May 2022.
- ^ a b c d "Increlex- mecasermin injection, solution". DailyMed. 7 May 2020. Retrieved 30 May 2022.
- ^ Fintini D, Brufani C, Cappa M (June 2009). "Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency". Therapeutics and Clinical Risk Management. 5 (3): 553–9. doi:10.2147/tcrm.s6178. PMC 2724186. PMID 19707272.
- ^ "Increlex". Drugs.com. Retrieved 10 January 2010.
- ^ a b "Iplex (mecasermin rinfabate [rDNA origin] injection) Package Insert" (PDF). U.S. Food and Drug Administration.
- ^ Keating GM (2008). "Mecasermin". BioDrugs. 22 (3): 177–188. doi:10.2165/00063030-200822030-00004. PMID 18481900.